Impact of age, body weight and metabolic risk factors on steroid reference intervals in men

in European Journal of Endocrinology
View More View Less
  • 1 Unit of Endocrinology and Prevention and Care of Diabetes, Center for Applied Biomedical Research, Department of Medical and Surgical Sciences, University of Bologna, S.Orsola Policlinic, Bologna, Italy

Correspondence should be addressed to F Fanelli; Email: flaminia.fanelli2@unibo.it

The journal and the authors apologise for errors in the above article published in the May 2020 isuue (vol 182 Iss 5 pp 459–471) of the European Journal of Endocrinology. The legend to Figure 2 has an error describing the lower and upper limits calculated in the reference and dysmetabolic sub-cohorts. The correct legend is published below.

Figure 2 Steroid lower and upper limits per year of age in reference and dysmetabolic sub-cohorts. Green lines and dots: lower and upper limits calculated in the reference sub-cohorts. Black lines and white dots: lower and upper limits calculated in the dysmetabolic sub-cohorts. *P < 0.05.

Further a number of errors have been found in Table 3 and the correct table is published in full here.

Table 3

Lower (LRL) and upper (URL) reference limits of age–dependent steroid hormones. Data are reported as the mean − 1.96 × s.d. and mean + 1.96 × s.d. of hormone distribution for LRL and URL, respectively, as calculated at every 5 years of adult age.

Age (years)
20253035404550556065
17OHP5
 LRL5.1 (41–6.3)4.8 (3.9–5.8)4.4 (3.6–5.2)4.0 (3.4–4.6)3.6 (3.0–4.0)3.2 (2.7–3.4)2.8 (2.3–3.0)2.4 (1.8–2.7)2.1 (1.4–2.4)1.8 (1.1–2.2)
 URL46.4 (35.1–68.6)42.4 (32.6–59.4)38.1 (30.0–50.1)33.5 (27.1–41.6)33.5 (27.1–41.6)33.5 (27.1–41.6)33.5 (27.1–41.6)33.5 (27.1–41.6)33.5 (27.1–41.6)33.5 (27.1–41.6)
DHEA
 LRL9.9 (8.4–11.4)9.2 (8.3–10.2)8.4 (7.7–9.1)7.5 (6.8–8.1)6.5 (5.9–7.0)5.6 (5.0–6.1)4.7 (4.1–5.2)3.8 (3.3–4.3)3.1 (2.5–3.6)2.4 (1.9–3.0)
 URL70.8 (58.9–87.4)64.0 (56.0–74.1)57.3 (51.6–64.1)50.4 (46.1–55.4)43.7 (40.3–47.8)37.2 (34.3–40.9)31.0 (28.5–34.5)25.5 (23.1–28.7)20.5 (18.3–23.5)16.2 (14.1–18.9)
17OHP4
 LRL1.50 (1.13–1.71)1.46 (1.12–1.65)1.43 (1.11–1.60)1.40 (1.11–1.55)1.39 (1.12–1.52)1.38 (1.13–1.51)1.39 (1.15–1.54)1.41 (1.15–1.61)1.45 (1.15–1.74)1.50 (1.15–1.92)
 URL7.36 (6.57–8.05)7.17 (6.45–7.77)6.95 (6.33–7.47)6.72 (6.16–7.17)6.47 (5.96–6.86)6.19 (5.73–6.61)5.90 (5.42–6.39)5.58 (5.05–6.21)5.23 (4.61–6.02)4.87 (4.11–5.84)
Cort. (B)
 LRL3.5 (2.8–5.0)3.3 (2.8–4.7)3.1 (2.7–4.3)3.0 (2.6–4.0)2.8 (2.5–3.6)2.6 (2.4–3.4)2.4 (2.1–3.2)2.2 (1.8–3.2)2.0 (1.4–3.3)1.9 (1.1–3.4)
 URL53.0 (46.0–77.3)50.9 (44.7–72.6)48.4 (43.1–67.3)45.4 (41.3–61.6)42.1 (39.0–55.3)38.6 (36.4–49.2)34.8 (33.4–43.9)30.9 (29.5–39.6)27.0 (25.0–36.4)23.1 (20.4–33.5)
11S
 LRL0.24 (0.19–0.31)0.24 (0.19–0.30)0.24 (0.20–0.29)0.24 (0.21–0.28)0.24 (0.21–0.28)0.25 (0.21–0.28)0.25 (0.21–0.28)0.25 (0.21–0.30)0.26 (0.20–0.32)0.26 (0.19–0.34)
 URL3.65 (3.15–4.40)3.55 (3.12–4.21)3.45 (3.08–4.02)3.34 (3.02–3.83)3.23 (2.94–3.63)3.11 (2.83–3.49)2.99 (2.70–3.40)2.87 (2.55–3.34)2.74 (2.36–3.28)2.61 (2.17–3.24)
Cortisol
 LRL152 (111–182)154 (119–180)156 (126–177)158 (134–176)160 (141–176)162 (144–177)165 (145–181)167 (143–186)169 (140–192)171 (137–198)
 URL598 (564–645)584 (554–624)569 (544–603)555 (533–584)541 (521–566)527 (508–550)513 (494–538)499 (477–527)485 (459–516)471 (441–506)
A4
 LRL1.20 (1.08–1.30)1.15 (1.04–1.24)1.10 (1.00–1.18)1.06 (0.97–1.12)1.02 (0.94–1.08)0.99 (0.91–1.05)0.96 (0.89–1.03)0.94 (0.86–1.02)0.93 (0.83–1.02)0.92 (0.80–1.04)
 URL5.13 (4.58–5.85)4.85 (4.39–5.45)4.57 (4.19–5.05)4.30 (3.99–4.67)4.02 (3.78–4.31)3.75 (3.55–3.97)3.48 (3.30–3.69)3.21 (3.00–3.47)2.95 (2.68–3.26)2.69 (2.37–3.07)

A4, androstenedione; Cort. (B), cortisosterone; 11S, 11-deoxycortisol; 17OHP5, 17-hydroxypregnenolone; 17OHP4, 17-hydroxyprogesterone.

If the inline PDF is not rendering correctly, you can download the PDF file here.

 

     European Society of Endocrinology